Loading
Life sciences · Journal article
International Journal of Medical & Pharmaceutical Sciences · August 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a narrative literature review summarizing the clinical and genetic features of Hutchinson–Gilford Progeria Syndrome and highlighting emerging therapeutic approaches including lonafarnib, mTOR inhibitors, antisense oligonucleotide therapy, and CRISPR-Cas9. It provides a synthesis of existing knowledge rather than new empirical evidence and does not evaluate the efficacy or safety of any specific treatment through controlled trial data.
Narrative literature review. Children with Hutchinson–Gilford Progeria Syndrome, a rare genetic disorder of accelerated aging.
HGPS is caused by mutations in the LMNA gene resulting in accumulation of abnormal progerin protein Clinical manifestations typically develop within the first two years of life and include growth retardation, alopecia, lipodystrophy, and skeletal abnormalities Cardiovascular complications are the leading cause of mortality with average life expectancy of approximately 14–15 years
Cardiovascular complications are the leading cause of mortality with average life expectancy of approximately 14–15 years
This review provides clinicians with a comprehensive summary of HGPS pathophysiology, clinical presentation, and diagnostic approaches. It emphasizes the role of early molecular genetic diagnosis and multidisciplinary management, and identifies emerging therapies that may offer future treatment options, though efficacy data from controlled trials are not presented here.
A narrative literature review synthesizing existing knowledge on HGPS epidemiology, pathophysiology, and emerging therapies; descriptive in nature without primary data, controlled trials, or novel empirical findings.
As stated by the source record.
Quoted from the source exactly as published.
This review provides clinicians with a comprehensive summary of HGPS pathophysiology, clinical presentation, and diagnostic approaches. It emphasizes the role of early molecular genetic diagnosis and multidisciplinary management, and identifies emerging therapies that may offer future treatment options, though efficacy data from controlled trials are not presented here.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Hutchinson–Gilford Progeria Syndrome (HGPS) is a rare, progressive genetic disorder characterized by accelerated aging in children due to mutations in the LMNA gene, resulting in the accumulation of the abnormal protein progerin. Although affected children appear healthy at birth, clinical manifestations such as growth retardation, alopecia, lipodystrophy, skeletal abnormalities, and premature cardiovascular disease typically develop within the first two years of life. Cardiovascular complications remain the leading cause of mortality, with an average life expectancy of approximately 14–15 years. This literature review summarizes the epidemiology, genetic basis, molecular pathophysiology, clinical manifestations, diagnostic approaches, and current management strategies for HGPS. It also highlights recent therapeutic advances, including lonafarnib, mTOR inhibitors, antisense oligonucleotide therapy, and gene-editing technologies such as CRISPR-Cas9 protein, which offer promising future treatment options. Early diagnosis through molecular genetic testing and multidisciplinary management are essential for improving survival and quality of life. Continued research into disease mechanisms and targeted therapies is crucial for developing effective long-term treatments for this devastating disorder.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.